Department of Pathology, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
Division of Cancer Predisposition, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
Genes Chromosomes Cancer. 2024 Jan;63(1):e23195. doi: 10.1002/gcc.23195. Epub 2023 Aug 7.
Rhabdoid Tumor Predisposition Syndrome 1 (RTPS1) confers an increased risk of developing rhabdoid tumors and is caused by germline mutations in SMARCB1. RTPS1 should be evaluated in all individuals with rhabdoid tumor and is more likely in those with a young age at presentation (occasionally congenital presentation), multiple primary tumors, or a family history of rhabdoid tumor or RTPS1. Proband genetic testing is the standard method for diagnosing RTPS1. Most known RTPS1-related SMARCB1 gene mutations are copy number variants (CNVs) or single nucleotide variants/indels, but structural variant analysis (SVA) is not usually included in the molecular evaluation. Here, we report two children with RTPS1 presenting with atypical teratoid/rhabdoid tumor (ATRT) who had constitutional testing showing balanced chromosome translocations involving SMARCB1. Patient 1 is a 23-year-old female diagnosed with pineal region ATRT at 7 months who was found to have a de novo, constitutional t(16;22)(p13.3;q11.2). Patient 2 is a 24-month-old male diagnosed with a posterior fossa ATRT at 14 months, with subsequent testing showing a constitutional t(5;22)(q14.1;q11.23). These structural rearrangements have not been previously reported in RTPS1. While rare, these cases suggest that structural variants should be considered in the evaluation of children with rhabdoid tumors to provide more accurate genetic counseling on the risks of developing tumors, the need for surveillance, and the risks of passing the disorder on to future children. Further research is needed to understand the prevalence, clinical features, and tumor risks associated with RTPS1-related constitutional balanced translocations.
横纹肌瘤病易感性综合征 1(RTPS1)会增加罹患横纹肌瘤的风险,由 SMARCB1 种系突变引起。RTPS1 应在所有横纹肌瘤患者中进行评估,并且更可能发生在具有以下特征的患者中:发病年龄较小(偶尔为先天性)、多个原发性肿瘤或横纹肌瘤或 RTPS1 的家族史。先证者基因检测是诊断 RTPS1 的标准方法。大多数已知的 RTPS1 相关 SMARCB1 基因突变是拷贝数变异(CNVs)或单核苷酸变异/缺失,但结构变异分析(SVA)通常不包括在分子评估中。在这里,我们报告了两例具有 RTPS1 的横纹肌瘤病患者,他们表现为非典型畸胎瘤/横纹肌瘤(ATRT),经检测发现存在涉及 SMARCB1 的染色体平衡易位。患者 1 是一名 23 岁女性,7 个月时被诊断为松果体区 ATRT,发现存在新发、先天性 t(16;22)(p13.3;q11.2)。患者 2 是一名 24 月龄男性,14 个月时被诊断为后颅窝 ATRT,随后的检测显示存在先天性 t(5;22)(q14.1;q11.23)。这些结构重排以前没有在 RTPS1 中报道过。虽然很少见,但这些病例表明,在评估横纹肌瘤患儿时应考虑结构变异,以便更准确地遗传咨询肿瘤发生风险、监测需求以及将疾病遗传给未来孩子的风险。需要进一步研究以了解与 RTPS1 相关的先天性平衡易位的流行率、临床特征和肿瘤风险。